Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q4 2015 · 10-K
Revenue$23.04M$23.04M−81.9% vs Q4 2014 Net Income-$32.42M-$32.42MN/M vs Q4 2014 EPS Diluted-$0.31-$0.31N/M vs Q4 2014 Operating Income-$31,330,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$48,939,000N/M Margins · derivedOperating margin-136.0%−205.4 pt vs Q4 2014
Net margin-140.7%−208.9 pt vs Q4 2014
ended Dec 31, 2016 · filed Mar 6, 2017 · 65 d after period end